Osteosarcoma is one of the most common primary malignant bone
tumors in children and adolescents. Some patients continue to have a poor prognosis, because of the metastatic disease.
YM529/ONO-5920 is a
nitrogen-containing
bisphosphonate that has been used for the treatment of
osteoporosis.
YM529/ONO-5920 has recently been reported to induce apoptosis in various
tumors including
osteosarcoma. However, the mode of
metastasis suppression in
osteosarcoma by
YM529/ONO-5920 is unclear. In the present study, we investigated whether
YM529/ONO-5920 inhibited
tumor cell migration, invasion, adhesion, or
metastasis in the LM8 mouse
osteosarcoma cell line. We found that
YM529/ONO-5920 significantly inhibited
metastasis, cell migration, invasion, and adhesion at concentrations that did not have antiproliferative effects on LM8 cells.
YM529/ONO-5920 also inhibited the
mRNA expression and
protein activities of
matrix metalloproteinases (
MMPs). In addition,
YM529/ONO-5920 suppressed phosphorylated
extracellular signal-regulated kinase 1/2 (ERK1/2) and the
serine/threonine protein kinase B (Akt) by the inhibition of Ras prenylation. Moreover,
U0126, a
mitogen-activated protein kinase kinase (
MEK) 1/2 inhibitor, and
LY294002, a
phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and
metastasis, as well as the
mRNA expression and
protein activities of MMP-1, MMP-2, MMP-9, and
MT1-MMP. The results indicated that
YM529/ONO-5920 suppressed the Ras/
MEK/ERK and Ras/PI3K/Akt pathways, thereby inhibiting LM8 cell migration, invasion, adhesion, and
metastasis. These findings suggest that
YM529/ONO-5920 has potential clinical applications for the treatment of
tumor cell
metastasis in
osteosarcoma.